Johnson & Johnson (JNJ)

$160.30 0.35 (0.22%)

19:59 EST JNJ Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 429.95B

PE Ratio 348.48

EPS 0.46

Volume (Avg. Vol.) 7.63M

Day's Range 159.11 - 161.41

52-Week Range 109.16 - 161.95

Dividend & Yield 3.48 (2.17%)

JNJ Stock Predictions, Articles, and Johnson & Johnson News

From InvestorPlace
From the Web

7 Pharmaceutical Stocks With Exciting Plans for 2021

By Bret Kenwell, InvestorPlace Contributor Jan 13, 2021

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

8 Value Stocks That Could Perform Surprisingly Well In 2021

By Josh Enomoto, InvestorPlace Contributor Jan 11, 2021

With growth names still flying high, value stocks to buy doesn’t exactly inspire excitement. Nevertheless, it could be the most prudent choice ahead of an uncertain 2021.

The Top 7 Pharmaceutical Stocks for the Next 10 Years

By Alex Sirois Jan 11, 2021

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

7 Coronavirus Stocks to Buy to Make Mass Vaccination Possible

By Divya Premkumar, InvestorPlace Contributor Jan 5, 2021

The Covid-19 vaccine rally isn’t just limited to biotech firms. Here are the top coronavirus stocks that are making mass vaccination possible.

8 Dental Stocks If You Want to Clean Up

By Josh Enomoto, InvestorPlace Contributor Dec 31, 2020

As the Covid-19 pandemic worsens, the case for dental stocks to buy might not seem too bright. However, this sector is a very broad one, with upside opportunities available right now.

The 12 Best Stocks to Buy for a Whole New Year of Returns in 2021

By Will Ashworth, InvestorPlace Contributor Dec 23, 2020

It’s time to start considering some of the best stocks to buy for 2021. However, these 12 selections come with a bit of a twist.

7 of the Best Dividend Aristocrats on the Market

By Bret Kenwell, InvestorPlace Contributor Dec 18, 2020

Just because a stock pays a dividend, does not mean that yield is safe. Let's look at the best dividend stocks to own going forward.

7 Long-Term Stocks for Buffett-Like Investors

By Joel Baglole Dec 17, 2020

Warren Buffett is famous for his buy-and-hold style. In this article, we look at seven long-term stocks for Buffet-inspired investors.

7 Undervalued Stocks That You Shouldn’t Pass On

By Ian Bezek, InvestorPlace Contributor Dec 15, 2020

As you make portfolio adjustments heading into 2021, these seven undervalued stocks could be just what you're looking for.

8 Retirement Stocks You Can Rely On

By Josh Enomoto, InvestorPlace Contributor Dec 14, 2020

While happening stocks are getting most of the attention in the new normal, smart buyers should consider retirement investments that are proven to be reliable for the long haul.

Investment Breakdown: The Best Stock in Each Sector of the Market

By Josh Enomoto, InvestorPlace Contributor Dec 9, 2020

With a pandemic and politics colliding, it’s a confusing time to be an investor. But you can improve the odds by banking on the best stock in each sector.

7 Blue-Chip Stocks You Can Trust

By Tom Taulli, InvestorPlace Writer & IPO Playbook Editor Dec 8, 2020

With the markets reaching new highs, it might be time to get defensive, and that means considering these seven blue-chip stocks.

3 Dividend Stocks for Big Total Returns in 2021

By Muslim Farooque Dec 3, 2020

These dividend stocks continue to outperform thier competition in yielding higher and consistent returns despite the impact of the pandemic

7 Undervalued Stocks to Snap Up Today

By Todd Shriber, InvestorPlace Contributor Dec 3, 2020

There aren't many undervalued stocks out there, but some familiar, quality names fit the bill. We've pulled that list together for you.

4 Healthcare Stocks That Will Take Care of You

By Faisal Humayun Nov 30, 2020

These healthcare stocks can deliver steady growth in the coming decade as demographics suggest tailwinds for the industry.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

By Josh Enomoto, InvestorPlace Contributor Nov 24, 2020

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

Johnson & Johnson Is an Excellent Dividend Growth Stock

By Ian Bezek, InvestorPlace Contributor Nov 24, 2020

Johnson & Johnson is trading at its historic fair valuation. In today's frothy market, that makes JNJ stock quite a good blue chip holding.

7 Hot Stocks to Buy Before 2021 Ushers in Change

By Alex Sirois Nov 20, 2020

These 7 stocks to buy before 2021 were strong in 2020 and have the characteristics to remain strong next year. Click for more.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond

By Bret Kenwell, InvestorPlace Contributor Nov 17, 2020

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.

9 Outbreak-Fueled Stocks to Buy This Week

By Josh Enomoto, InvestorPlace Contributor Nov 11, 2020

While coronavirus numbers start to subside again, many investors are in a pandemic mentality, making these the stocks to buy this week.

South Africa, which has yet to receive its first coronavirus vaccine, has been promised 9 million doses by Johnson & Johnson, the Business Day newspaper reported on Monday, citing a health ministry spokeswoman. The government of Africa's most advanced economy is scrambling to secure enough COVID-19 vaccines, after health workers and scientists publicly criticised it for not moving fast enough to inoculate its people. The country has recorded more than 1.3 million infections and more than 37,000 deaths related to the virus, the most in Africa.

The New York Post: Fauci says two more COVID-19 vaccines could be approved within ‘weeks’

From Marketwatch Jan 18, 2021

Dr. Anthony Fauci on Sunday that Johnson & Johnson and AstraZeneca could send studies of their COVID-19 vaccines to the feds for approval within “weeks.”

Fauci says 2 new vaccines could be ready for US approval within weeks, not months

From BusinessInsider Jan 18, 2021

Dr. Anthony Fauci said AstraZeneca and Johnson & Johnson's vaccines, still in clinical trials, could be submitted for FDA approval within a week.

Navellier Ratings

Total Grade

Hold

Johnson & Johnson (JNJ)

JNJ Stock Predictions, Articles, and Johnson & Johnson News

Navellier Ratings

Total Grade

Subscriber Sign in